CINRYZE (C1 esterase inhibitor [human]), antifibrinolytic

Substantial clinical benefit in the treatment of angioedema attacks and in their short- and long-term prevention, but no clinical benefit demonstrated in children in the treatment of this disease

• CINRYZE has Marketing Authorisation in children aged 2 years and older in the treatment and pre-procedure prevention of angioedema attacks and for routine prevention of angioedema attacks in children aged 6 years and older.
• Efficacy in paediatrics has been demonstrated with a low level of evidence, because it is based on post-hoc analyses in sub-groups or in non-comparative studies.
• There is no data demonstrative of the impact of CINRYZE on quality of life of children or on the organisation of care.